CO5601020A2 - Compuestos ox-azabiciclicos - Google Patents

Compuestos ox-azabiciclicos

Info

Publication number
CO5601020A2
CO5601020A2 CO04082792A CO04082792A CO5601020A2 CO 5601020 A2 CO5601020 A2 CO 5601020A2 CO 04082792 A CO04082792 A CO 04082792A CO 04082792 A CO04082792 A CO 04082792A CO 5601020 A2 CO5601020 A2 CO 5601020A2
Authority
CO
Colombia
Prior art keywords
alkyl
group
hydrogen
independently
represent
Prior art date
Application number
CO04082792A
Other languages
English (en)
Inventor
Bernard Gaudilliere
Henry Jacobelli
Catherine Kostlan
Jack Li
Yue Wen-Song
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CO5601020A2 publication Critical patent/CO5601020A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/91Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

1.- Un compuesto seleccionado de aquellos de la fórmula (I):caracterizado porque:? X1, X2 y X3, independientemente uno de otro, representan un átomo de nitrógeno o un grupo -CR3 en donde R3 representa un grupo seleccionado de hidrógeno, alquilo (de C1-C6), amino, monoalquilamino (de C1-C6), dialquilamino (de C1-C6), hidroxi, alcoxi (de C1-C6) y halógeno, con la condición de que no más de dos de los grupos X1, X2 y X3 simultáneamente representen un átomo de nitrógeno,? G1 representa un grupo seleccionado de aquellos de lasfórmulas (i/a) e (i/b): en donde:- el átomo de carbono con el número 2 está unido al grupo N-R1 del anillo,- R4 y R5, idénticos o diferentes, independientemente uno de otro, representan un grupo seleccionado de hidrógeno, alquilo (de C1-C6), arilo, arilalquilo (de C1-C6), cicloalquilo, cicloalquilalquilo (de C1-C6), heteroarilo, heteroarilalquilo (de C1-C6), heterocicloalquilo, y heterocicloalquilalquilo (de C1-C6),- R4 representa un grupo seleccionado de: hidrógeno, trifluorometilo, OR7, NR7R8, en donde R7 y R8, idénticos o diferentes independientemente uno de otro, representan hidrógeno o alquilo (de C1-C6), alquilo (de C1-C6), alquenilo (de C2-C6), alquinilo (de C2-C6), arilo, arilalquilo (de C1-C6), cicloalquilalquilo (de C1-C6), heteroarilo, heteroarilalquilo (de C1-C6), heterocicloalquilo, y heterocicloalquilalquilo (de C1-C6), estos grupos son optativamente sustituidos por uno o más grupos, que pueden ser idénticos o diferentes independientemente uno de otro, seleccionados de halógeno, amino, monoalquilamino (de C1-C6), dialquilamino (de C1-C6), cada grupo alquilo es idéntico o diferente independientemente uno de otro, ...
CO04082792A 2002-03-08 2004-08-25 Compuestos ox-azabiciclicos CO5601020A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/003240 WO2003076416A1 (en) 2002-03-08 2002-03-08 Oxo azabicyclic compounds

Publications (1)

Publication Number Publication Date
CO5601020A2 true CO5601020A2 (es) 2006-01-31

Family

ID=27798761

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04082792A CO5601020A2 (es) 2002-03-08 2004-08-25 Compuestos ox-azabiciclicos

Country Status (25)

Country Link
EP (1) EP1492775A2 (es)
JP (1) JP2005526070A (es)
KR (1) KR20040095270A (es)
CN (1) CN1738806A (es)
AP (1) AP2004003125A0 (es)
AR (1) AR039562A1 (es)
AU (2) AU2002249275A1 (es)
BR (1) BR0308280A (es)
CA (1) CA2478706A1 (es)
CO (1) CO5601020A2 (es)
EA (1) EA200401053A1 (es)
EC (1) ECSP045278A (es)
IL (1) IL163818A0 (es)
IS (1) IS7414A (es)
MA (1) MA27183A1 (es)
MX (1) MXPA04008681A (es)
NO (1) NO20044041L (es)
OA (1) OA12782A (es)
PA (1) PA8568501A1 (es)
PE (1) PE20031018A1 (es)
PL (1) PL372622A1 (es)
SV (1) SV2003001495A (es)
TN (1) TNSN04169A1 (es)
UY (1) UY27700A1 (es)
WO (2) WO2003076416A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003249531A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
BR0313459A (pt) 2002-08-13 2005-06-21 Warner Lambert Co Derivados monocìclicos como inibidores de metaloproteinases de matriz
CA2497658A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
JP2006500351A (ja) 2002-08-13 2006-01-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテアーゼ−13阻害剤としてのピリミジン−2,4−ジオン誘導体
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
WO2004014923A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
MXPA06012333A (es) * 2004-04-30 2007-01-17 Takeda Pharmaceutical Compuesto de amida heterociclico y uso del mismo como un inhibidor mmp-13.
KR20070028536A (ko) * 2004-06-15 2007-03-12 아스트라제네카 아베 항암제로서의 치환된 퀴나졸론
CN101522676A (zh) 2006-10-05 2009-09-02 Cv医药有限公司 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物
WO2012052451A1 (en) 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
KR20180052631A (ko) 2015-09-23 2018-05-18 얀센 파마슈티카 엔.브이. 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0946095A1 (en) * 1996-12-17 1999-10-06 E.I. Du Pont De Nemours And Company Fungicidal quinazolinones
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13

Also Published As

Publication number Publication date
NO20044041L (no) 2004-10-07
KR20040095270A (ko) 2004-11-12
MA27183A1 (fr) 2005-01-03
MXPA04008681A (es) 2004-12-06
IS7414A (is) 2004-08-19
CA2478706A1 (en) 2003-09-18
AU2003212307A1 (en) 2003-09-22
PE20031018A1 (es) 2004-01-09
AU2002249275A1 (en) 2003-09-22
WO2003076417A3 (en) 2003-11-13
ECSP045278A (es) 2004-10-26
TNSN04169A1 (fr) 2007-03-12
AR039562A1 (es) 2005-02-23
PA8568501A1 (es) 2003-12-19
JP2005526070A (ja) 2005-09-02
WO2003076416A1 (en) 2003-09-18
CN1738806A (zh) 2006-02-22
IL163818A0 (en) 2005-12-18
OA12782A (en) 2006-07-10
UY27700A1 (es) 2003-10-31
BR0308280A (pt) 2004-12-28
EP1492775A2 (en) 2005-01-05
PL372622A1 (en) 2005-07-25
EA200401053A1 (ru) 2005-04-28
WO2003076417A2 (en) 2003-09-18
SV2003001495A (es) 2003-11-04
AP2004003125A0 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
CO5601020A2 (es) Compuestos ox-azabiciclicos
ECSP034730A (es) Quinazolinas como inhibidores de mmp-13
CO5580747A2 (es) Derivados e intermediarios de n-adamantilmetilo como composiciones farmaceuticas y procesos para su preparacion
ES2120535T3 (es) Agentes reticulantes con trifuncionalidad de carbamato.
CO5601018A2 (es) Derivados de n-fenil-2-pirimidin-amina
CO5560573A2 (es) Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen
ATE338461T1 (de) Pyrazolpyrimidinfungizide
AR013693A1 (es) Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
PA8547601A1 (es) Inhibidores de la proteasa del vih, composiciones que los contienen, sus usos farmaceuticos y materiales para su sintesis
MY138145A (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
CO5690643A2 (es) Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
ES2193839B1 (es) Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
NO20052976L (no) Fosfodiesterase-4-inhibitorer.
ES2179005T3 (es) Compuesto de cromeno.
HRP20070132T3 (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
EE9800266A (et) Analgeetikumidena kasutatavad isokinoliinid
AR066606A1 (es) Compuestos de heteroarilamida pirimidona
ATE360045T1 (de) Polycarbonatzusammensetzungen
HUP0402227A2 (hu) Fenil-szubsztituált triazolok és az AKL5 kináz szelektív inhibitoraiként történő felhasználásuk és a vegyületeket tartalmazó gyógyszerkészítmények
CO5690648A2 (es) Analogos novedosos de acido 2´,5´-oligoadenilico
UA86013C2 (ru) Производные арилалкилкарбаматов, их получение и применение в лечении
PA8575001A1 (es) Fluorobenzamidas como inhibidores de maob
ES2106185T3 (es) 3-carboxiesteroides 17-beta-sustituidos no saturados.

Legal Events

Date Code Title Description
FA Application withdrawn